ES2610654T3 - Anticuerpos neutralizantes del receptor de prolactina y su uso terapéutico - Google Patents
Anticuerpos neutralizantes del receptor de prolactina y su uso terapéutico Download PDFInfo
- Publication number
- ES2610654T3 ES2610654T3 ES10782255.3T ES10782255T ES2610654T3 ES 2610654 T3 ES2610654 T3 ES 2610654T3 ES 10782255 T ES10782255 T ES 10782255T ES 2610654 T3 ES2610654 T3 ES 2610654T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- prlr
- corresponds
- antibody
- prolactin receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100029000 Prolactin receptor Human genes 0.000 title abstract description 41
- 108010002519 Prolactin Receptors Proteins 0.000 title abstract 4
- 230000003472 neutralizing effect Effects 0.000 title description 7
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract description 12
- 102000036639 antigens Human genes 0.000 abstract description 12
- 108091007433 antigens Proteins 0.000 abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 8
- 239000012634 fragment Substances 0.000 abstract description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 6
- 150000007523 nucleic acids Chemical group 0.000 abstract description 6
- 230000001404 mediated effect Effects 0.000 abstract description 5
- 230000011664 signaling Effects 0.000 abstract description 5
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 22
- 238000011282 treatment Methods 0.000 description 12
- 201000009273 Endometriosis Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 102000003946 Prolactin Human genes 0.000 description 10
- 108010057464 Prolactin Proteins 0.000 description 10
- 239000000583 progesterone congener Substances 0.000 description 10
- 229940097325 prolactin Drugs 0.000 description 10
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 7
- 101100409237 Homo sapiens PRLR gene Proteins 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 210000004696 endometrium Anatomy 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 206010014522 Embolism venous Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 201000009274 endometriosis of uterus Diseases 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 208000004043 venous thromboembolism Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 239000003217 oral combined contraceptive Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000005641 Adenomyosis Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 101100409239 Mus musculus Prlr gene Proteins 0.000 description 3
- 210000000579 abdominal fat Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004246 corpus luteum Anatomy 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010006298 Breast pain Diseases 0.000 description 2
- 208000006662 Mastodynia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 208000011803 breast fibrocystic disease Diseases 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000006213 vaginal ring Substances 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 101100450694 Arabidopsis thaliana HFR1 gene Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100353203 Rattus norvegicus Prlr gene Proteins 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008267 autocrine signaling Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000003152 gestagenic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000001190 hypoprolactinemic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09075546 | 2009-12-10 | ||
| EP09075546A EP2332995A1 (en) | 2009-12-10 | 2009-12-10 | Neutralizing prolactin receptor antibodies and their therapeutic use |
| PCT/EP2010/067742 WO2011069795A1 (en) | 2009-12-10 | 2010-11-18 | Neutralizing prolactin receptor antibodies and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2610654T3 true ES2610654T3 (es) | 2017-04-28 |
Family
ID=42091520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10782255.3T Active ES2610654T3 (es) | 2009-12-10 | 2010-11-18 | Anticuerpos neutralizantes del receptor de prolactina y su uso terapéutico |
| ES10776753.5T Active ES2603352T3 (es) | 2009-12-10 | 2010-11-18 | Anticuerpos neutralizantes contra el receptor de prolactina y su uso terapéutico |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10776753.5T Active ES2603352T3 (es) | 2009-12-10 | 2010-11-18 | Anticuerpos neutralizantes contra el receptor de prolactina y su uso terapéutico |
Country Status (40)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| DK3345615T3 (da) | 2010-03-01 | 2020-01-20 | Bayer Healthcare Llc | Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi) |
| EP2530089A1 (en) | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| EA036225B1 (ru) | 2012-03-14 | 2020-10-15 | Ридженерон Фармасьютикалз, Инк. | Мультиспецифические антигенсвязывающие молекулы и их применения |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| DK2935331T3 (en) | 2012-12-24 | 2018-06-06 | Abbvie Inc | PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF |
| CN105025925A (zh) * | 2013-03-15 | 2015-11-04 | 拜尔健康护理有限责任公司 | 抗-催乳素受体抗体制剂 |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| WO2015168474A1 (en) | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
| CN117442748A (zh) | 2014-10-02 | 2024-01-26 | 希望之城公司 | 多价中间表位、中间表位结合抗体及其用途 |
| KR20170105558A (ko) | 2015-01-30 | 2017-09-19 | 각코우호우징 사이타마이카다이가쿠 | 항 alk2 항체 |
| JP6993958B2 (ja) | 2015-07-06 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性抗原結合分子およびその使用 |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| MX2019006131A (es) | 2016-11-29 | 2019-08-21 | Regeneron Pharma | Metodos para tratar cancer de mama positivo para prlr. |
| FR3062213B1 (fr) * | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| JP2020519639A (ja) * | 2017-05-12 | 2020-07-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | トリアザスピロ［４．５］デカノンによる胃不全麻痺の処置 |
| US20210128728A1 (en) | 2017-07-10 | 2021-05-06 | Bayer Pharma Aktiengesellschaft | Prolactin receptor antibody for male and female pattern hair loss |
| AU2019218892B2 (en) | 2018-02-07 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| WO2019169330A1 (en) * | 2018-03-02 | 2019-09-06 | Oncolix, Inc. | Method for treating cancers expressing prolactin receptor |
| CN109627340B (zh) * | 2018-12-05 | 2021-02-12 | 上海交通大学 | Cd3和prlr双特异性抗体及其构建与应用 |
| US10467487B1 (en) * | 2018-12-11 | 2019-11-05 | Chongqing Jinkang New Energy Automobile Co., Ltd. | Fusion-based traffic light recognition for autonomous driving |
| CN112425568A (zh) * | 2020-12-11 | 2021-03-02 | 上海市计划生育科学研究所 | 一种建立具有emt特征的良性前列腺增生bph犬模型的方法 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CN114853890B (zh) * | 2022-03-16 | 2023-04-28 | 沈阳三生制药有限责任公司 | 一种prlr抗原结合蛋白及其制备方法和应用 |
| CN114634574B (zh) * | 2022-04-18 | 2022-12-20 | 先进生物(苏州)有限公司 | 抗B7H6的scFv抗体、其编码基因及其应用 |
| CN118834297A (zh) * | 2023-04-24 | 2024-10-25 | 深圳真实生物医药科技有限公司 | 泌乳素受体抗体及其用途 |
| CN117285625B (zh) * | 2023-11-24 | 2024-01-23 | 南京佰抗生物科技有限公司 | 抗泌乳素蛋白的单克隆抗体及应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4986615A (en) | 1988-10-17 | 1991-01-22 | The Vendo Company | Vending apparatus |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| GB9105245D0 (en) * | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| JP2001500865A (ja) * | 1996-09-13 | 2001-01-23 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | 避妊の非ホルモン法 |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| US6867187B2 (en) * | 2000-12-22 | 2005-03-15 | Trustees Of The University Of Pennsylvania | Composition and method for modulating somatolactogenic function |
| EP1325930A1 (en) * | 2002-01-08 | 2003-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mammal prolactin variants |
| AU2003300904A1 (en) * | 2002-12-13 | 2004-07-09 | The Ohio State University | Antagonists for human prolactin |
| GB0305790D0 (en) * | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Novel Composition |
| ATE541585T1 (de) * | 2004-10-28 | 2012-02-15 | Kyowa Hakko Kirin Co Ltd | Antikörper gegen il-5-rezeptor zur verwendung in der behandlung von endometriose. |
| WO2006089678A2 (en) * | 2005-02-22 | 2006-08-31 | Bioinvent International Ab | Antibodies and peptides binding to hiv tat, and uses thereof |
| GB0517878D0 (en) * | 2005-09-02 | 2005-10-12 | Bioinvent Int Ab | Immunotherapeutic treatment |
| US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| EP2423231A3 (en) * | 2006-08-18 | 2012-05-30 | Novartis AG | PRLR-specific antibody and uses thereof |
| CN102711773A (zh) | 2007-05-30 | 2012-10-03 | 奥克兰联合服务有限公司 | 生长激素和相关激素的抑制剂,和其使用方法 |
| EP2025683A1 (en) * | 2007-08-13 | 2009-02-18 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Variants of prolactin as antagonists of its receptor |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| WO2011139375A1 (en) * | 2010-05-06 | 2011-11-10 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against carbonic anhydrase ix and methods and uses thereof |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
-
2009
- 2009-12-10 EP EP09075546A patent/EP2332995A1/en not_active Withdrawn
-
2010
- 2010-11-18 LT LTEP10776753.5T patent/LT2510002T/lt unknown
- 2010-11-18 PH PH1/2012/501131A patent/PH12012501131A1/en unknown
- 2010-11-18 NZ NZ600511A patent/NZ600511A/en unknown
- 2010-11-18 EP EP10784482A patent/EP2510007A1/en not_active Withdrawn
- 2010-11-18 DK DK10776753.5T patent/DK2510002T3/en active
- 2010-11-18 JP JP2012542434A patent/JP2013513363A/ja active Pending
- 2010-11-18 EP EP12192705A patent/EP2567978A1/en not_active Withdrawn
- 2010-11-18 PE PE2012000791A patent/PE20121360A1/es not_active Application Discontinuation
- 2010-11-18 PE PE2012000797A patent/PE20121561A1/es not_active Application Discontinuation
- 2010-11-18 EP EP12192722A patent/EP2567980A1/en not_active Withdrawn
- 2010-11-18 SI SI201031367A patent/SI2510006T1/sl unknown
- 2010-11-18 CA CA2783513A patent/CA2783513C/en active Active
- 2010-11-18 CN CN201080063268XA patent/CN102858801A/zh active Pending
- 2010-11-18 EP EP10782255.3A patent/EP2510006B1/en active Active
- 2010-11-18 US US13/514,993 patent/US20130171147A1/en not_active Abandoned
- 2010-11-18 BR BR112012014048-5A patent/BR112012014048B1/pt active IP Right Grant
- 2010-11-18 RS RS20170010A patent/RS55589B1/sr unknown
- 2010-11-18 EP EP10781882A patent/EP2510005A1/en not_active Withdrawn
- 2010-11-18 HU HUE10776753A patent/HUE031631T2/en unknown
- 2010-11-18 WO PCT/EP2010/067744 patent/WO2011069797A1/en not_active Ceased
- 2010-11-18 WO PCT/EP2010/067747 patent/WO2011069799A1/en not_active Ceased
- 2010-11-18 EP EP12192708A patent/EP2567979A1/en not_active Withdrawn
- 2010-11-18 MX MX2012006620A patent/MX339343B/es active IP Right Grant
- 2010-11-18 SG SG2012041166A patent/SG181511A1/en unknown
- 2010-11-18 US US13/514,996 patent/US9241989B2/en active Active
- 2010-11-18 JP JP2012542436A patent/JP6066474B2/ja active Active
- 2010-11-18 CN CN201080063347.0A patent/CN102947338B/zh active Active
- 2010-11-18 CA CA2783678A patent/CA2783678A1/en not_active Abandoned
- 2010-11-18 RS RS20160915A patent/RS55277B1/sr unknown
- 2010-11-18 MX MX2012006621A patent/MX2012006621A/es unknown
- 2010-11-18 MA MA34951A patent/MA33888B1/fr unknown
- 2010-11-18 WO PCT/EP2010/067746 patent/WO2011069798A1/en not_active Ceased
- 2010-11-18 EP EP12192707A patent/EP2570435A1/en not_active Withdrawn
- 2010-11-18 EP EP10776753.5A patent/EP2510002B1/en active Active
- 2010-11-18 PE PE2017000782A patent/PE20171134A1/es unknown
- 2010-11-18 ES ES10782255.3T patent/ES2610654T3/es active Active
- 2010-11-18 KR KR1020127017833A patent/KR101790366B1/ko active Active
- 2010-11-18 SI SI201031312A patent/SI2510002T1/sl unknown
- 2010-11-18 HR HRP20170016TT patent/HRP20170016T1/hr unknown
- 2010-11-18 CA CA2783514A patent/CA2783514A1/en not_active Abandoned
- 2010-11-18 JP JP2012542432A patent/JP2013513361A/ja active Pending
- 2010-11-18 US US13/514,991 patent/US20120321632A1/en not_active Abandoned
- 2010-11-18 ES ES10776753.5T patent/ES2603352T3/es active Active
- 2010-11-18 KR KR1020127017831A patent/KR101765968B1/ko active Active
- 2010-11-18 ME MEP-2016-244A patent/ME02577B/me unknown
- 2010-11-18 CA CA2783651A patent/CA2783651A1/en not_active Abandoned
- 2010-11-18 NZ NZ600512A patent/NZ600512A/en unknown
- 2010-11-18 AU AU2010330165A patent/AU2010330165B2/en active Active
- 2010-11-18 CA CA2783654A patent/CA2783654A1/en not_active Abandoned
- 2010-11-18 CN CN2010800633485A patent/CN102741291A/zh active Pending
- 2010-11-18 CN CN2010800634492A patent/CN102858804A/zh active Pending
- 2010-11-18 WO PCT/EP2010/067743 patent/WO2011069796A1/en not_active Ceased
- 2010-11-18 PL PL10776753T patent/PL2510002T3/pl unknown
- 2010-11-18 WO PCT/EP2010/067742 patent/WO2011069795A1/en not_active Ceased
- 2010-11-18 CN CN201080063269.4A patent/CN102884082B/zh active Active
- 2010-11-18 HU HUE10782255A patent/HUE030143T2/en unknown
- 2010-11-18 US US13/514,995 patent/US20130022606A1/en not_active Abandoned
- 2010-11-18 IN IN5078DEN2012 patent/IN2012DN05078A/en unknown
- 2010-11-18 US US13/514,994 patent/US20120315276A1/en not_active Abandoned
- 2010-11-18 PT PT107822553T patent/PT2510006T/pt unknown
- 2010-11-18 EA EA201200851A patent/EA029327B1/ru not_active IP Right Cessation
- 2010-11-18 IN IN5082DEN2012 patent/IN2012DN05082A/en unknown
- 2010-11-18 EP EP12192704A patent/EP2567977A1/en not_active Withdrawn
- 2010-11-18 EP EP10779014A patent/EP2510003A1/en not_active Withdrawn
- 2010-11-18 PL PL10782255T patent/PL2510006T3/pl unknown
- 2010-11-18 BR BR112012015852A patent/BR112012015852B8/pt active IP Right Grant
- 2010-11-18 JP JP2012542433A patent/JP2013513362A/ja active Pending
- 2010-11-18 LT LTEP10782255.3T patent/LT2510006T/lt unknown
- 2010-11-18 JP JP2012542431A patent/JP2013513559A/ja active Pending
- 2010-11-18 PH PH1/2012/501129A patent/PH12012501129A1/en unknown
- 2010-11-18 EP EP12192721A patent/EP2570436A1/en not_active Withdrawn
- 2010-11-18 SG SG2012041182A patent/SG181513A1/en unknown
- 2010-11-18 AP AP2012006343A patent/AP2012006343A0/xx unknown
- 2010-11-18 DK DK10782255.3T patent/DK2510006T3/en active
- 2010-11-18 HR HRP20161401TT patent/HRP20161401T1/hr unknown
- 2010-11-18 PT PT107767535T patent/PT2510002T/pt unknown
- 2010-11-18 WO PCT/EP2010/067740 patent/WO2011069794A1/en not_active Ceased
- 2010-11-18 EA EA201200860A patent/EA028678B1/ru not_active IP Right Cessation
- 2010-11-18 CA CA2783610A patent/CA2783610C/en active Active
- 2010-11-18 AU AU2010330161A patent/AU2010330161B2/en active Active
- 2010-11-18 US US13/514,992 patent/US9649374B2/en active Active
- 2010-11-18 JP JP2012542435A patent/JP2013513364A/ja not_active Ceased
- 2010-11-18 EP EP10781671A patent/EP2510004A1/en not_active Withdrawn
- 2010-11-18 CN CN2010800634488A patent/CN102858803A/zh active Pending
- 2010-12-10 AR ARP100104564A patent/AR079349A1/es unknown
- 2010-12-10 TW TW099143328A patent/TWI487536B/zh active
- 2010-12-10 TW TW099143327A patent/TW201130504A/zh unknown
- 2010-12-10 TW TW099143326A patent/TW201138817A/zh unknown
- 2010-12-10 AR ARP100104566A patent/AR079351A1/es unknown
- 2010-12-10 TW TW099143332A patent/TWI508744B/zh active
- 2010-12-10 AR ARP100104567A patent/AR079352A1/es active IP Right Grant
- 2010-12-10 AR ARP100104565A patent/AR079350A1/es unknown
- 2010-12-10 TW TW099143330A patent/TW201130506A/zh unknown
- 2010-12-10 AR ARP100104563A patent/AR079348A1/es active IP Right Grant
- 2010-12-17 AR ARP100104707A patent/AR079641A1/es unknown
-
2012
- 2012-06-04 IL IL220149A patent/IL220149A/en active IP Right Grant
- 2012-06-04 IL IL220151A patent/IL220151A0/en active IP Right Grant
- 2012-06-07 CU CU2012000093A patent/CU23973B1/es not_active IP Right Cessation
- 2012-06-07 CU CU2012000092A patent/CU20120092A7/es unknown
- 2012-06-08 EC ECSP12011965 patent/ECSP12011965A/es unknown
- 2012-06-08 CR CR20120312A patent/CR20120312A/es unknown
- 2012-06-08 DO DO2012000159A patent/DOP2012000159A/es unknown
- 2012-06-08 ZA ZA2012/04213A patent/ZA201204213B/en unknown
- 2012-06-08 DO DO2012000160A patent/DOP2012000160A/es unknown
- 2012-06-08 EC ECSP12011966 patent/ECSP12011966A/es unknown
- 2012-06-08 CL CL2012001540A patent/CL2012001540A1/es unknown
- 2012-06-08 ZA ZA2012/04214A patent/ZA201204214B/en unknown
- 2012-06-08 GT GT201200186A patent/GT201200186A/es unknown
- 2012-06-08 CR CR20120310A patent/CR20120310A/es unknown
- 2012-06-08 CL CL2012001539A patent/CL2012001539A1/es unknown
- 2012-06-08 TN TNP2012000294A patent/TN2012000294A1/en unknown
-
2015
- 2015-07-03 JP JP2015134286A patent/JP6199930B2/ja active Active
-
2016
- 2016-10-31 CY CY20161101101T patent/CY1118209T1/el unknown
-
2017
- 2017-01-10 CY CY20171100030T patent/CY1118407T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2610654T3 (es) | Anticuerpos neutralizantes del receptor de prolactina y su uso terapéutico | |
| Vercellini et al. | Endometriosis: current and future medical therapies | |
| Hess et al. | Oviduct and Endometrium: Cyclic Changes | |
| EA031017B1 (ru) | Способ поддержания или замещения фазы жёлтого тела | |
| ES2690782T3 (es) | Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro | |
| PL192784B1 (pl) | Zastosowanie kwasu nukleinowego | |
| Critchley et al. | Regulation of bcl-2 gene family members in human endometrium by antiprogestin administration in vivo | |
| Hermanny et al. | In vitro assessment of some sperm function following exposure to levonorgestrel in human fallopian tubes | |
| RU2013123792A (ru) | Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний | |
| EA003927B1 (ru) | Антагонисты фактора опухолевого некроза и их применение при эндометриозе | |
| Sillem et al. | Endometrial integrin expression is independent of estrogen or progestin treatment in vitro | |
| Islimye et al. | Regression of endometrial autografts in a rat model of endometriosis treated with etanercept | |
| Li et al. | Immunization of male mice with B-cell epitopes in transmembrane domains of CatSper1 inhibits fertility | |
| RU2014122158A (ru) | Медицинское применение | |
| Jabeen et al. | Causes of primary amenorrhea at tertiary level hospital | |
| Luo et al. | Immunogenicity study of plasmid DNA encoding mouse cysteine‐rich secretory protein‐1 (mCRISP 1) as a contraceptive vaccine | |
| Ahmed et al. | Potential effect of Imatinib on some sex hormones for male patients of Chronic Myelogenous Leukemia in Baghdad province | |
| Onyeso et al. | Role of Progestins in Reproduction | |
| Hapangama | Mifepristone: the multifaceted antihormone | |
| Tripathy | The Fallopian Tubes | |
| Dumakude | Prophylactic HPV vaccines effects in preventing and managing cervical cancer | |
| Basavarajappa et al. | Toxicity of the pregnant female reproductive system | |
| Hussein | Environmental Risk Factors for Infertility Focusing on Egypt: A Narrative Review | |
| Javed et al. | CAUSES OF PRIMARY AMENORRHEA AMONG PATIENT PRESENTING AT A TERTIARY CARE HOSPITAL | |
| Pachnicki et al. | Hormonal Contraception in Breast Cancer Survivors: From Hormonal Physiology to Future Perspectives. Medical Research Archives,[online] 13 (8) |